文献速递MDS 与骨髓增殖性肿瘤白血病

BCR-JAK2融合MPN经芦可替尼治疗后发生淋系母细胞转化及耐药机制分析

Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance.
PubMed 文献 · Blood Adv · 2021-01-01

本文报道一例携带BCR-JAK2融合的骨髓增殖性肿瘤(MPN)患者,经芦可替尼治疗获得初始血液学反应后迅速发生B淋系母细胞转化。通过基因组测序、MPseq、RNA-seq和染色体微阵列分析,发现转化时出现新的IKZF1拷贝数缺失及B细胞受体样信号激活表型,未发现BCR-JAK2融合基因或转录本耐药突变。

要点

  • BCR-JAK2融合MPN患者芦可替尼治疗中可发生B淋系母细胞转化。
  • 转化时新发IKZF1拷贝数缺失,未见BCR-JAK2融合本身耐药突变。
  • 耐药机制涉及IKZF1缺失及向活化BCR样信号表型转换。

核心结论

  • IKZF1缺失和从细胞因子依赖向活化BCR样信号表型转换是该例芦可替尼耐药的推定机制。

研究设计与样本

  • 单例病例报告,分析芦可替尼治疗前和母细胞转化时的样本。

主要发现

  • 未发现BCR-JAK2融合基因或转录本的耐药突变,融合转录本表达水平保持稳定。
  • 母细胞转化时MPseq检出新的IKZF1拷贝数缺失,预测导致正常IKZF1蛋白翻译丢失。
  • RNA-seq显示受IKZF1负调控的基因显著上调,包括IL7R和CRLF2。
  • 疾病进展伴随向活化B细胞受体样信号表型适应,CD79A、CD79B、IGLL1、VPREB1、BLNK、ZAP70、RAG1和RAG2等基因显著上调。

临床怎么用

  • 对BCR-JAK2融合MPN患者芦可替尼治疗中出现疾病进展时,应警惕淋系母细胞转化。

局限性

  • 本文为单例病例报告,所提耐药机制为推定性质,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The basis for acquired resistance to JAK inhibition in patients with JAK2-driven hematologic malignancies is not well understood. We report a patient with a myeloproliferative neoplasm (MPN) with a BCR activator of RhoGEF and GTPase (BCR)-JAK2 fusion with initial hematologic response to ruxolitinib who rapidly developed B-lymphoid blast transformation. We analyzed pre-ruxolitinib and blast transformation samples using genome sequencing, DNA mate-pair sequencing (MPseq), RNA sequencing (RNA-seq), and chromosomal microarray to characterize possible mechanisms of resistance. No resistance mutations in the BCR-JAK2 fusion gene or transcript were identified, and fusion transcript expression levels remained stable. However, at the time of blast transformation, MPseq detected a new IKZF1 copy-number loss, which is predicted to result in loss of normal IKZF1 protein translation. RNA-seq revealed significant upregulation of genes negatively regulated by IKZF1, including IL7R and CRLF2. Disease progression was also characterized by adaptation to an activated B-cell receptor (BCR)-like signaling phenotype, with marked upregulation of genes such as CD79A, CD79B, IGLL1, VPREB1, BLNK, ZAP70, RAG1, and RAG2. In summary, IKZF1 deletion and a switch from cytokine dependence to activated BCR-like signaling phenotype represent putative mechanisms of ruxolitinib resistance in this case, recapitulating preclinical data on resistance to JAK inhibition in CRLF2-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Chen JA, Hou Y, Roskin KM, et al. Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance. Blood Adv. 2021. PMID: 34505882. doi:10.1182/bloodadvances.2020004174

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。